JP2010540443A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010540443A5 JP2010540443A5 JP2010525902A JP2010525902A JP2010540443A5 JP 2010540443 A5 JP2010540443 A5 JP 2010540443A5 JP 2010525902 A JP2010525902 A JP 2010525902A JP 2010525902 A JP2010525902 A JP 2010525902A JP 2010540443 A5 JP2010540443 A5 JP 2010540443A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pyridin
- compound
- formula
- ylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 89
- -1 1,2-dihydroxyethyl Chemical group 0.000 claims description 22
- 229910052801 chlorine Inorganic materials 0.000 claims description 15
- 229910052794 bromium Inorganic materials 0.000 claims description 14
- 125000004429 atom Chemical group 0.000 claims description 12
- 229910052751 metal Inorganic materials 0.000 claims description 10
- 239000002184 metal Substances 0.000 claims description 10
- 229910052731 fluorine Inorganic materials 0.000 claims description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 8
- 239000003054 catalyst Substances 0.000 claims description 8
- 125000006239 protecting group Chemical group 0.000 claims description 5
- WOSBCVOGVFCSBF-KRWDZBQOSA-N (1r)-1-[2-[[3-(4-fluorophenoxy)-5-pyridin-2-ylsulfanylpyridin-2-yl]amino]-1,3-thiazol-4-yl]ethane-1,2-diol Chemical compound OC[C@H](O)C1=CSC(NC=2C(=CC(SC=3N=CC=CC=3)=CN=2)OC=2C=CC(F)=CC=2)=N1 WOSBCVOGVFCSBF-KRWDZBQOSA-N 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 73
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 239000003153 chemical reaction reagent Substances 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000004076 pyridyl group Chemical group 0.000 claims 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 5
- 102000030595 Glucokinase Human genes 0.000 claims 4
- 108010021582 Glucokinase Proteins 0.000 claims 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 4
- 150000001450 anions Chemical class 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 125000002524 organometallic group Chemical group 0.000 claims 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- PCOMIRCNMMNOAP-CQSZACIVSA-N (1s)-1-[5-[[3-(2-methylpyridin-3-yl)oxy-5-pyridin-2-ylsulfanylpyridin-2-yl]amino]-1,2,4-thiadiazol-3-yl]ethane-1,2-diol Chemical compound CC1=NC=CC=C1OC1=CC(SC=2N=CC=CC=2)=CN=C1NC1=NC([C@H](O)CO)=NS1 PCOMIRCNMMNOAP-CQSZACIVSA-N 0.000 claims 2
- GMWTVCFRMOODKB-OXJNMPFZSA-N (1s,2s)-1-[5-[[3-(2-ethylpyridin-3-yl)oxy-5-pyridin-2-ylsulfanylpyridin-2-yl]amino]-1,2,4-thiadiazol-3-yl]-3-methoxypropane-1,2-diol Chemical compound CCC1=NC=CC=C1OC1=CC(SC=2N=CC=CC=2)=CN=C1NC1=NC([C@H](O)[C@@H](O)COC)=NS1 GMWTVCFRMOODKB-OXJNMPFZSA-N 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 150000002009 diols Chemical class 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 150000004678 hydrides Chemical class 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 229910052987 metal hydride Inorganic materials 0.000 claims 2
- 150000004681 metal hydrides Chemical class 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229910052763 palladium Inorganic materials 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- HHNGEWOVAIAEOR-LBPRGKRZSA-N (1r)-1-[2-[[5-bromo-3-(2-methylpyridin-3-yl)oxypyridin-2-yl]amino]-1,3-thiazol-4-yl]ethane-1,2-diol Chemical compound CC1=NC=CC=C1OC1=CC(Br)=CN=C1NC1=NC([C@@H](O)CO)=CS1 HHNGEWOVAIAEOR-LBPRGKRZSA-N 0.000 claims 1
- MYLATRMZFDLPQN-ZDUSSCGKSA-N (1r)-1-[2-[[5-bromo-3-(4-fluorophenoxy)pyridin-2-yl]amino]-1,3-thiazol-4-yl]ethane-1,2-diol Chemical compound OC[C@H](O)C1=CSC(NC=2C(=CC(Br)=CN=2)OC=2C=CC(F)=CC=2)=N1 MYLATRMZFDLPQN-ZDUSSCGKSA-N 0.000 claims 1
- PCOMIRCNMMNOAP-AWEZNQCLSA-N (1r)-1-[5-[[3-(2-methylpyridin-3-yl)oxy-5-pyridin-2-ylsulfanylpyridin-2-yl]amino]-1,2,4-thiadiazol-3-yl]ethane-1,2-diol Chemical compound CC1=NC=CC=C1OC1=CC(SC=2N=CC=CC=2)=CN=C1NC1=NC([C@@H](O)CO)=NS1 PCOMIRCNMMNOAP-AWEZNQCLSA-N 0.000 claims 1
- MYLATRMZFDLPQN-CYBMUJFWSA-N (1s)-1-[2-[[5-bromo-3-(4-fluorophenoxy)pyridin-2-yl]amino]-1,3-thiazol-4-yl]ethane-1,2-diol Chemical compound OC[C@@H](O)C1=CSC(NC=2C(=CC(Br)=CN=2)OC=2C=CC(F)=CC=2)=N1 MYLATRMZFDLPQN-CYBMUJFWSA-N 0.000 claims 1
- CTXDVRKMQHVHGH-CQSZACIVSA-N (1s)-1-[5-[[3-(1-methylpyrazol-4-yl)oxy-5-(2-methylpyridin-3-yl)sulfanylpyridin-2-yl]amino]-1,2,4-thiadiazol-3-yl]ethane-1,2-diol Chemical compound CC1=NC=CC=C1SC(C=C1OC2=CN(C)N=C2)=CN=C1NC1=NC([C@H](O)CO)=NS1 CTXDVRKMQHVHGH-CQSZACIVSA-N 0.000 claims 1
- RWQZSJMFUPEMDW-OAHLLOKOSA-N (1s)-1-[5-[[3-(2,4-dimethylpyridin-3-yl)oxy-5-pyridin-2-ylsulfanylpyridin-2-yl]amino]-1,2,4-thiadiazol-3-yl]ethane-1,2-diol Chemical compound CC1=CC=NC(C)=C1OC1=CC(SC=2N=CC=CC=2)=CN=C1NC1=NC([C@H](O)CO)=NS1 RWQZSJMFUPEMDW-OAHLLOKOSA-N 0.000 claims 1
- NARRNXGFBLOLIN-OAHLLOKOSA-N (1s)-1-[5-[[3-(2,6-dimethylpyridin-3-yl)oxy-5-pyridin-2-ylsulfanylpyridin-2-yl]amino]-1,2,4-thiadiazol-3-yl]ethane-1,2-diol Chemical compound CC1=NC(C)=CC=C1OC1=CC(SC=2N=CC=CC=2)=CN=C1NC1=NC([C@H](O)CO)=NS1 NARRNXGFBLOLIN-OAHLLOKOSA-N 0.000 claims 1
- WRGNMIHQQVHYFZ-KRWDZBQOSA-N (1s)-1-[5-[[3-(2-ethylpyrazol-3-yl)oxy-5-pyridin-2-ylsulfanylpyridin-2-yl]amino]-1,2,4-thiadiazol-3-yl]-2-methylpropane-1,2-diol Chemical compound CCN1N=CC=C1OC1=CC(SC=2N=CC=CC=2)=CN=C1NC1=NC([C@H](O)C(C)(C)O)=NS1 WRGNMIHQQVHYFZ-KRWDZBQOSA-N 0.000 claims 1
- RZVUDIMEUMEXCG-CYBMUJFWSA-N (1s)-1-[5-[[3-(2-ethylpyrazol-3-yl)oxy-5-pyridin-2-ylsulfanylpyridin-2-yl]amino]-1,2,4-thiadiazol-3-yl]ethane-1,2-diol Chemical compound CCN1N=CC=C1OC1=CC(SC=2N=CC=CC=2)=CN=C1NC1=NC([C@H](O)CO)=NS1 RZVUDIMEUMEXCG-CYBMUJFWSA-N 0.000 claims 1
- CMRJZYKOQTWELR-OAHLLOKOSA-N (1s)-1-[5-[[3-(2-ethylpyridin-3-yl)oxy-5-pyridin-2-ylsulfanylpyridin-2-yl]amino]-1,2,4-thiadiazol-3-yl]ethane-1,2-diol Chemical compound CCC1=NC=CC=C1OC1=CC(SC=2N=CC=CC=2)=CN=C1NC1=NC([C@H](O)CO)=NS1 CMRJZYKOQTWELR-OAHLLOKOSA-N 0.000 claims 1
- PQBSOIOZQZTXKC-SNVBAGLBSA-N (1s)-1-[5-[[3-(2-methylpyridin-3-yl)oxy-5-(trifluoromethyl)pyridin-2-yl]amino]-1,2,4-thiadiazol-3-yl]ethane-1,2-diol Chemical compound CC1=NC=CC=C1OC1=CC(C(F)(F)F)=CN=C1NC1=NC([C@H](O)CO)=NS1 PQBSOIOZQZTXKC-SNVBAGLBSA-N 0.000 claims 1
- TUJVXTJGINHJHX-CYBMUJFWSA-N (1s)-1-[5-[[5-(2-methoxyethylsulfanyl)-3-(1,3,5-trimethylpyrazol-4-yl)oxypyridin-2-yl]amino]-1,2,4-thiadiazol-3-yl]ethane-1,2-diol Chemical compound CC1=NN(C)C(C)=C1OC1=CC(SCCOC)=CN=C1NC1=NC([C@H](O)CO)=NS1 TUJVXTJGINHJHX-CYBMUJFWSA-N 0.000 claims 1
- BLUFSDNPSHXGMW-SECBINFHSA-N (1s)-1-[5-[[5-bromo-3-(1-methylpyrazol-4-yl)oxypyridin-2-yl]amino]-1,2,4-thiadiazol-3-yl]ethane-1,2-diol Chemical compound C1=NN(C)C=C1OC1=CC(Br)=CN=C1NC1=NC([C@H](O)CO)=NS1 BLUFSDNPSHXGMW-SECBINFHSA-N 0.000 claims 1
- VDRBYJONNNJAJX-KWCCSABGSA-N (1s)-1-[5-[[5-bromo-3-(5,6,7,8-tetrahydroquinolin-5-yloxy)pyridin-2-yl]amino]-1,2,4-thiadiazol-3-yl]ethane-1,2-diol Chemical compound OC[C@@H](O)C1=NSC(NC=2C(=CC(Br)=CN=2)OC2C3=CC=CN=C3CCC2)=N1 VDRBYJONNNJAJX-KWCCSABGSA-N 0.000 claims 1
- INVNRFIMHJOKOG-SNVBAGLBSA-N (1s)-1-[5-[[5-bromo-3-[1-(2-hydroxyethyl)pyrazol-4-yl]oxypyridin-2-yl]amino]-1,2,4-thiadiazol-3-yl]ethane-1,2-diol Chemical compound C1=NN(CCO)C=C1OC1=CC(Br)=CN=C1NC1=NC([C@H](O)CO)=NS1 INVNRFIMHJOKOG-SNVBAGLBSA-N 0.000 claims 1
- AKHBJHAXSQCBPM-SFHVURJKSA-N (1s)-2-methyl-1-[5-[[3-(2-methylpyridin-3-yl)oxy-5-pyridin-2-ylsulfanylpyridin-2-yl]amino]-1,2,4-thiadiazol-3-yl]propane-1,2-diol Chemical compound CC1=NC=CC=C1OC1=CC(SC=2N=CC=CC=2)=CN=C1NC1=NC([C@H](O)C(C)(C)O)=NS1 AKHBJHAXSQCBPM-SFHVURJKSA-N 0.000 claims 1
- BCZBRQMUBHFQDM-SFHVURJKSA-N (1s)-2-methyl-1-[5-[[5-pyridin-2-ylsulfanyl-3-(1,3,5-trimethylpyrazol-4-yl)oxypyridin-2-yl]amino]-1,2,4-thiadiazol-3-yl]propane-1,2-diol Chemical compound CC1=NN(C)C(C)=C1OC1=CC(SC=2N=CC=CC=2)=CN=C1NC1=NC([C@H](O)C(C)(C)O)=NS1 BCZBRQMUBHFQDM-SFHVURJKSA-N 0.000 claims 1
- VENYHQCOHUORPB-NRFANRHFSA-N (2r)-2-[5-[[3-(2-methylpyridin-3-yl)oxy-5-pyridin-2-ylsulfanylpyridin-2-yl]amino]-1,2,4-thiadiazol-3-yl]propane-1,2-diol Chemical compound CC1=NC=CC=C1OC1=CC(SC=2N=CC=CC=2)=CN=C1NC1=NC([C@@](C)(O)CO)=NS1 VENYHQCOHUORPB-NRFANRHFSA-N 0.000 claims 1
- VENYHQCOHUORPB-OAQYLSRUSA-N (2s)-2-[5-[[3-(2-methylpyridin-3-yl)oxy-5-pyridin-2-ylsulfanylpyridin-2-yl]amino]-1,2,4-thiadiazol-3-yl]propane-1,2-diol Chemical compound CC1=NC=CC=C1OC1=CC(SC=2N=CC=CC=2)=CN=C1NC1=NC([C@](C)(O)CO)=NS1 VENYHQCOHUORPB-OAQYLSRUSA-N 0.000 claims 1
- QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 239000004146 Propane-1,2-diol Substances 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 239000010949 copper Substances 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 239000007800 oxidant agent Substances 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229960004063 propylene glycol Drugs 0.000 claims 1
- 235000013772 propylene glycol Nutrition 0.000 claims 1
- 125000004497 pyrazol-5-yl group Chemical group N1N=CC=C1* 0.000 claims 1
- 238000000034 method Methods 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000460 chlorine Substances 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 8
- 239000002585 base Substances 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 150000003927 aminopyridines Chemical class 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 4
- FFNVQNRYTPFDDP-UHFFFAOYSA-N 2-cyanopyridine Chemical compound N#CC1=CC=CC=N1 FFNVQNRYTPFDDP-UHFFFAOYSA-N 0.000 description 4
- 0 COc1cc(S)cnc1NC1=S*C(*)=N1 Chemical compound COc1cc(S)cnc1NC1=S*C(*)=N1 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 150000003930 2-aminopyridines Chemical class 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- ABNQGNFVSFKJGI-UHFFFAOYSA-N 2,3-dichloro-5-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CN=C(Cl)C(Cl)=C1 ABNQGNFVSFKJGI-UHFFFAOYSA-N 0.000 description 2
- CZBSVYBVNUPBMP-UHFFFAOYSA-N 3-(4-fluorophenoxy)-5-pyridin-2-ylsulfanylpyridine-2-carbonitrile Chemical compound C1=CC(F)=CC=C1OC1=CC(SC=2N=CC=CC=2)=CN=C1C#N CZBSVYBVNUPBMP-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- FFHWBOKNEWHENY-UHFFFAOYSA-N 5-bromo-3-(2,6-dimethylpyridin-3-yl)oxypyridin-2-amine Chemical compound CC1=NC(C)=CC=C1OC1=CC(Br)=CN=C1N FFHWBOKNEWHENY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 2
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- ALKLYKZTRLFBBD-OAHLLOKOSA-N (1s)-1-[5-[[3-(4-fluorophenoxy)-5-pyridin-2-ylsulfanylpyridin-2-yl]amino]-1,2,4-thiadiazol-3-yl]ethane-1,2-diol Chemical compound OC[C@@H](O)C1=NSC(NC=2C(=CC(SC=3N=CC=CC=3)=CN=2)OC=2C=CC(F)=CC=2)=N1 ALKLYKZTRLFBBD-OAHLLOKOSA-N 0.000 description 1
- REVBYCNXEFJPIH-GFCCVEGCSA-N (1s)-1-[5-[[5-(2-hydroxyethylsulfanyl)-3-(2-methylpyridin-3-yl)oxypyridin-2-yl]amino]-1,2,4-thiadiazol-3-yl]ethane-1,2-diol Chemical compound CC1=NC=CC=C1OC1=CC(SCCO)=CN=C1NC1=NC([C@H](O)CO)=NS1 REVBYCNXEFJPIH-GFCCVEGCSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- GZGPRZYZKBQPBQ-UHFFFAOYSA-N 1,4-dioxaspiro[4.5]decane Chemical compound O1CCOC11CCCCC1 GZGPRZYZKBQPBQ-UHFFFAOYSA-N 0.000 description 1
- NUMGEMJDCLWFBZ-UHFFFAOYSA-N 2-(pyridin-3-yldisulfanyl)pyridine Chemical compound C=1C=CN=CC=1SSC1=CC=CC=N1 NUMGEMJDCLWFBZ-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- JDVCTNYPGHLBCJ-UHFFFAOYSA-N 3-(4-fluorophenoxy)-5-pyridin-2-ylsulfanylpyridin-2-amine Chemical compound C1=C(OC=2C=CC(F)=CC=2)C(N)=NC=C1SC1=CC=CC=N1 JDVCTNYPGHLBCJ-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- KPJVQALQDOFVSG-UHFFFAOYSA-N 5-bromo-3-(2,6-dimethylpyridin-3-yl)oxypyridine-2-carbonitrile Chemical compound CC1=NC(C)=CC=C1OC1=CC(Br)=CN=C1C#N KPJVQALQDOFVSG-UHFFFAOYSA-N 0.000 description 1
- UNNZIBVSIUTMEM-UHFFFAOYSA-N 5-bromo-3-(2,6-dimethylpyridin-3-yl)oxypyridine-2-carboxamide Chemical compound CC1=NC(C)=CC=C1OC1=CC(Br)=CN=C1C(N)=O UNNZIBVSIUTMEM-UHFFFAOYSA-N 0.000 description 1
- BXYTVMGTQBQUPF-UHFFFAOYSA-N 5-bromo-3-(2-fluorophenoxy)pyridin-2-amine Chemical compound NC1=NC=C(Br)C=C1OC1=CC=CC=C1F BXYTVMGTQBQUPF-UHFFFAOYSA-N 0.000 description 1
- ICZNWYWLGWYNFS-UHFFFAOYSA-N 5-bromo-3-(2-methylpyridin-3-yl)oxypyridine-2-carbonitrile Chemical compound CC1=NC=CC=C1OC1=CC(Br)=CN=C1C#N ICZNWYWLGWYNFS-UHFFFAOYSA-N 0.000 description 1
- JYGJDNYONVDRIQ-UHFFFAOYSA-N 5-bromo-3-(4-fluorophenoxy)pyridine-2-carbonitrile Chemical compound C1=CC(F)=CC=C1OC1=CC(Br)=CN=C1C#N JYGJDNYONVDRIQ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 238000006105 Hofmann reaction Methods 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001804 chlorine Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- WHMDPDGBKYUEMW-UHFFFAOYSA-N pyridine-2-thiol Chemical compound SC1=CC=CC=N1 WHMDPDGBKYUEMW-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 1
- CRWJEUDFKNYSBX-UHFFFAOYSA-N sodium;hypobromite Chemical compound [Na+].Br[O-] CRWJEUDFKNYSBX-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97422507P | 2007-09-21 | 2007-09-21 | |
| US60/974,225 | 2007-09-21 | ||
| PCT/US2008/076401 WO2009042435A1 (en) | 2007-09-21 | 2008-09-15 | Pyridin-2 -yl-amino-i, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010540443A JP2010540443A (ja) | 2010-12-24 |
| JP2010540443A5 true JP2010540443A5 (cg-RX-API-DMAC7.html) | 2011-10-27 |
| JP5722037B2 JP5722037B2 (ja) | 2015-05-20 |
Family
ID=40250949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010525902A Expired - Fee Related JP5722037B2 (ja) | 2007-09-21 | 2008-09-15 | 糖尿病治療のためのグルコキナーゼ活性化剤としてのピリジン−2−イル−アミノ−1,2,4−チアジアゾール誘導体 |
Country Status (28)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2131656A4 (en) * | 2006-11-15 | 2011-12-07 | Forest Lab Holdings Ltd | phthalazine |
| EA019104B1 (ru) | 2007-09-21 | 2014-01-30 | Эррей Биофарма Инк. | Активаторы глюкокиназы |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| CA2800498C (en) | 2010-03-31 | 2021-11-16 | The Scripps Research Institute | Reprogramming cells |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| MX2013002208A (es) | 2010-08-23 | 2013-05-30 | Amgen Inc | Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. |
| KR20140051834A (ko) | 2011-03-09 | 2014-05-02 | 다이이찌 산쿄 가부시키가이샤 | 디피리딜아민 유도체 |
| WO2012138776A1 (en) | 2011-04-05 | 2012-10-11 | Amgen Inc. | Benzodioxepine and benzodioxine compounds that interact with glucokinase regulatory protein for the treatment of diabetes |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN104230892B (zh) * | 2011-11-09 | 2016-12-07 | 福建海西新药创制有限公司 | 一组提高激酶活性的化合物及其应用 |
| WO2013123444A1 (en) | 2012-02-17 | 2013-08-22 | Amgen Inc. | Sulfonyl compounds that interact with glucokinase regulatory protein |
| WO2013173382A1 (en) | 2012-05-15 | 2013-11-21 | Amgen Inc. | Benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein |
| EP2850057A4 (en) * | 2012-05-18 | 2016-01-27 | Amgen Inc | PROCESS FOR THE PREPARATION OF THIADIAZOLENE |
| US20150299182A1 (en) * | 2012-11-09 | 2015-10-22 | Amgen Inc. | Crystalline forms of (1s)-1-[5-(amino)-1,2,4-thiadiazol-3-yl]ethane-1,2-diol |
| WO2016059647A2 (en) * | 2014-10-13 | 2016-04-21 | SHRI CHHATRAPTI SHIVAJI COLLEGE Maharashtra, India) | Triaminotriazine picolinonitrile derivatives as potent reverse transcriptase inhibitor of hiv-1 |
| GB201714777D0 (en) | 2017-09-14 | 2017-11-01 | Univ London Queen Mary | Agent |
| BR112020008727A2 (pt) | 2017-10-30 | 2020-10-20 | Neuropore Therapies, Inc. | fenil sulfonil fenil triazol tionas substituídas e usos destas |
| BR112020024269A2 (pt) * | 2018-05-31 | 2021-02-23 | Hua Medicine (Shanghai) Ltd. | combinação farmacêutica, composição e formulação de combinação contendo ativador de glucoquinase e ativador de receptor ppar e métodos de preparação e usos dos mesmos |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3983246A (en) | 1974-04-04 | 1976-09-28 | Fmc Corporation | N-(sulfonyloxy) benzimidoyl halides as bactericidal or fungicidal agents |
| DE2949913A1 (de) * | 1979-12-12 | 1981-06-25 | Basf Ag, 6700 Ludwigshafen | Azofarbstoffe |
| EP0300688A1 (en) | 1987-07-21 | 1989-01-25 | FISONS plc | Pyrrole derivatives, process for their preparation and pharmaceutical compositions containing them |
| JPH0228168A (ja) * | 1988-04-14 | 1990-01-30 | Sankyo Co Ltd | チアゾール誘導体 |
| WO1993017681A1 (en) | 1992-03-02 | 1993-09-16 | Abbott Laboratories | Angiotensin ii receptor antagonists |
| WO1993024442A1 (fr) | 1992-05-29 | 1993-12-09 | Yamanouchi Pharmaceutical Co., Ltd. | Medicament renfermant un derive d'acide benzoique, et nouveau derive d'acide benzoique |
| JP3056788B2 (ja) | 1994-06-24 | 2000-06-26 | ユーロ−セルティーク,エス.エイ. | ホスホジエステラーゼivの阻害化合物および阻害方法 |
| GB9908410D0 (en) * | 1999-04-13 | 1999-06-09 | Pfizer Ltd | Pyridines |
| CA2366932C (en) | 1999-04-15 | 2009-08-25 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| HRP20010795A2 (en) | 1999-04-28 | 2003-02-28 | Aventis Pharma Gmbh | Di-aryl acid derivatives as ppar receptor ligands |
| US6465467B1 (en) | 1999-05-21 | 2002-10-15 | Biovitrum Ab | Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases |
| CA2374898C (en) | 1999-05-21 | 2009-12-08 | Biovitrum Ab | Pyrazinyl-piperazine compounds, their use and preparation |
| JP4144978B2 (ja) | 1999-09-09 | 2008-09-03 | 富士フイルム株式会社 | 1,2,4−チアジアゾール誘導体の合成法 |
| MXPA02002559A (es) | 1999-09-10 | 2002-07-30 | Merck & Co Inc | Inhibidores de tirosina cinasa. |
| CA2396693A1 (en) | 1999-12-28 | 2001-07-05 | Stephen T. Wrobleski | Cytokine, especially tnf-alpha, inhibitors |
| US6906067B2 (en) | 1999-12-28 | 2005-06-14 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-α expression |
| US20020065270A1 (en) | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
| US7345051B2 (en) | 2000-01-31 | 2008-03-18 | Genaera Corporation | Mucin synthesis inhibitors |
| DZ3398A1 (fr) | 2000-08-31 | 2002-03-07 | Pfizer Prod Inc | Derives pyrazole et leur utilisation comme inhibiteurs des proteines kinases |
| US20050209297A1 (en) | 2000-08-31 | 2005-09-22 | Pfizer Inc | Pyrazole derivatives |
| AU2002213467A1 (en) | 2000-10-11 | 2002-04-22 | Chemocentryx, Inc. | Modulation of ccr4 function |
| WO2002030357A2 (en) | 2000-10-11 | 2002-04-18 | Chemocentryx, Inc. | Compounds and methods for modulating ccr4 function |
| AU3950802A (en) | 2000-12-07 | 2002-06-18 | Cv Therapeutics Inc | Abca-1 elevating compounds |
| BR0116493A (pt) | 2000-12-21 | 2003-09-30 | Vertex Pharma | Compostos de pirazol úteis como inibidores de proteìna cinase |
| AU2002258400A1 (en) | 2001-02-16 | 2002-08-28 | Tularik Inc. | Methods of using pyrimidine-based antiviral agents |
| WO2002094264A1 (en) | 2001-05-23 | 2002-11-28 | Tularik Inc. | Ccr4 antagonists |
| CA2450934A1 (en) | 2001-06-19 | 2002-12-27 | Marco Dodier | Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
| PE20030008A1 (es) | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
| ATE316088T1 (de) * | 2001-06-22 | 2006-02-15 | Merck & Co Inc | Tyrosin-kinase inhibitoren |
| EP1465900B1 (en) | 2002-01-10 | 2008-05-14 | Bayer HealthCare AG | Rho-kinase inhibitors |
| ATE511858T1 (de) | 2002-02-05 | 2011-06-15 | Astellas Pharma Inc | 2,4,6-triamino-1,3,5-triazin-derivat |
| US6846928B2 (en) | 2002-03-15 | 2005-01-25 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| AU2003225800A1 (en) | 2002-03-15 | 2003-09-29 | Hayley Binch | Azolylaminoazine as inhibitors of protein kinases |
| US20040009981A1 (en) | 2002-03-15 | 2004-01-15 | David Bebbington | Compositions useful as inhibitors of protein kinases |
| WO2003077921A1 (en) | 2002-03-15 | 2003-09-25 | Vertex Pharmaceuticals, Inc. | Azinylaminoazoles as inhibitors of protein kinases |
| MXPA04009541A (es) | 2002-03-29 | 2005-01-25 | Chiron Corp | Benzazoles sustituidos y uso de los mismos como inhibidores de cinasa raf. |
| US8299108B2 (en) | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
| AU2003227360A1 (en) * | 2002-04-25 | 2003-11-10 | Yamanouchi Pharmaceutical Co., Ltd. | Novel amide derivatives or salts thereof |
| AU2003249369A1 (en) | 2002-06-21 | 2004-01-06 | Cellular Genomics, Inc. | Certain amino-substituted monocycles as kinase modulators |
| CN1691944A (zh) | 2002-08-09 | 2005-11-02 | 阿斯利康(瑞典)有限公司 | 作为代谢型谷氨酸受体-5调节剂的噁二唑 |
| WO2004024159A1 (en) | 2002-09-10 | 2004-03-25 | Scios Inc. | INHIBITORS OF TFGβ |
| PL375021A1 (en) | 2002-10-03 | 2005-11-14 | Novartis Ag | Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes |
| EP1558609A4 (en) | 2002-10-30 | 2008-05-28 | Merck & Co Inc | KINASE INHIBITORS |
| CA2755297A1 (en) | 2003-02-10 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes |
| US20040248850A1 (en) | 2003-02-11 | 2004-12-09 | Kemia, Inc. | Compounds for the treatment of HIV infection |
| BRPI0407283A (pt) | 2003-02-13 | 2006-01-31 | Banyu Pharma Co Ltd | Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade |
| ATE396731T1 (de) | 2003-03-25 | 2008-06-15 | Vertex Pharma | Thiazole zur verwendung als inhibitoren von protein-kinasen |
| US7244763B2 (en) | 2003-04-17 | 2007-07-17 | Warner Lambert Company Llc | Compounds that modulate PPAR activity and methods of preparation |
| CN1845915A (zh) | 2003-09-02 | 2006-10-11 | 默克公司 | 作为亲代谢谷氨酸受体-5的调节剂的联吡啶胺和醚类化合物 |
| US7470712B2 (en) | 2004-01-21 | 2008-12-30 | Bristol-Myers Squibb Company | Amino-benzazoles as P2Y1 receptor inhibitors |
| WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| AR049418A1 (es) | 2004-02-27 | 2006-08-02 | Bayer Pharmaceuticals Corp | Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes. |
| KR20050091462A (ko) | 2004-03-12 | 2005-09-15 | 한국과학기술연구원 | 푸로피리미딘 화합물 및 이를 포함하는 ddr2 티로신키나아제 활성 저해제 |
| AU2005223610B2 (en) | 2004-03-23 | 2008-05-29 | Banyu Pharmaceutical Co., Ltd. | Substituted quinazoline or pyridopyrimidine derivative |
| US7781451B2 (en) | 2004-04-02 | 2010-08-24 | Novartis Ag | Thiazolopyridine derivatives, pharmaceut ical conditions containing them and methods of treating glucokinase mediated conditions |
| US7642354B2 (en) | 2004-04-13 | 2010-01-05 | Icagen, Inc. | Polycyclic pyrazines as potassium ion channel modulators |
| EP1737852A2 (en) | 2004-04-13 | 2007-01-03 | Icagen, Inc. | Polycyclic pyridines as potassium ion channel modulators |
| TW200606129A (en) * | 2004-07-26 | 2006-02-16 | Chugai Pharmaceutical Co Ltd | Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same |
| EP1844023A1 (en) | 2004-12-31 | 2007-10-17 | Sk Chemicals Co., Ltd. | Quinazoline derivatives for the treatment and prevention of diabetes and obesity |
| MX2007008434A (es) | 2005-01-19 | 2007-07-25 | Squibb Bristol Myers Co | Derivados de 2-fenoxi-n-(1,3,4-tiadizol-2il)piridin-3-amina y compuestos relacionados como inhibidores del receptor p2y1 para el tratamiento de trastornos tromboembolicos. |
| DE102005025161A1 (de) | 2005-06-01 | 2006-12-07 | Phenion Gmbh & Co. Kg | Derivate des Pyrimidins und Triazins und deren Verwendung |
| US7737151B2 (en) | 2005-08-18 | 2010-06-15 | Vertex Pharmaceuticals Incorporated | Pyrazine kinase inhibitors |
| AU2006285834A1 (en) * | 2005-08-31 | 2007-03-08 | Astellas Pharma Inc. | Thiazole derivative |
| WO2007038387A2 (en) | 2005-09-23 | 2007-04-05 | Yale University | Compounds and methods for the treatment of viruses and cancer |
| EP1948652B1 (en) | 2005-11-01 | 2011-08-24 | Array Biopharma, Inc. | Glucokinase activators |
| JP5249770B2 (ja) | 2005-11-03 | 2013-07-31 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼインヒビターとして有用なアミノピリジン |
| KR20070052207A (ko) | 2005-11-16 | 2007-05-21 | 주식회사 엘지생명과학 | 신규한 kdr 억제제 |
| ATE508126T1 (de) | 2005-11-16 | 2011-05-15 | Vertex Pharma | Als kinaseinhibitoren geeignete aminopyrimidine |
| JP5236499B2 (ja) * | 2006-01-27 | 2013-07-17 | アレイ バイオファーマ、インコーポレイテッド | グルコキナーゼ活性化剤 |
| RS53981B1 (sr) * | 2006-03-24 | 2015-10-30 | Array Biopharma Inc. | Analozi 2-aminopiridina kao aktivatori glukokinaze |
| WO2007131953A1 (en) | 2006-05-12 | 2007-11-22 | Ab Science | A new process for the synthesis of 2-aminoxazole compounds |
| WO2008024963A1 (en) | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Benzene, pyridine, and pyridazine derivatives |
| TW200825060A (en) | 2006-10-26 | 2008-06-16 | Astrazeneca Ab | Chemical compounds |
| JP5208123B2 (ja) | 2006-12-08 | 2013-06-12 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| US8431713B2 (en) | 2007-01-24 | 2013-04-30 | Array Biopharma, Inc. | 2-aminopyridine derivatives as glucokinase activators |
| JP5450108B2 (ja) * | 2007-03-23 | 2014-03-26 | アレイ バイオファーマ、インコーポレイテッド | グルコキナーゼ活性化剤としての2−アミノピリジン類似体 |
| ES2470341T3 (es) | 2007-04-05 | 2014-06-23 | Amgen, Inc | Moduladores de la aurora cinasa y método de uso |
| US20090012091A1 (en) | 2007-07-02 | 2009-01-08 | Kinagen, Inc. | Oximide derivatives and their therapeutical application |
| WO2009022171A1 (en) | 2007-08-13 | 2009-02-19 | Astrazeneca Ab | Pyridinyiioxy pyridines as alk5 inhibitors |
| EA019104B1 (ru) | 2007-09-21 | 2014-01-30 | Эррей Биофарма Инк. | Активаторы глюкокиназы |
| KR20100090250A (ko) | 2007-10-09 | 2010-08-13 | 메르크 파텐트 게엠베하 | 글루코키나제 활성체로서 유용한 피리딘 유도체 |
-
2008
- 2008-09-15 EA EA201000515A patent/EA019104B1/ru not_active IP Right Cessation
- 2008-09-15 UA UAA201004782A patent/UA101166C2/ru unknown
- 2008-09-15 ES ES13186328.4T patent/ES2569734T3/es active Active
- 2008-09-15 HR HRP20120814AT patent/HRP20120814T1/hr unknown
- 2008-09-15 BR BRPI0816881 patent/BRPI0816881A2/pt not_active IP Right Cessation
- 2008-09-15 NZ NZ583538A patent/NZ583538A/en not_active IP Right Cessation
- 2008-09-15 CN CN2008801169950A patent/CN101868459B/zh not_active Expired - Fee Related
- 2008-09-15 PL PL08834504T patent/PL2209778T3/pl unknown
- 2008-09-15 MX MX2010002772A patent/MX2010002772A/es active IP Right Grant
- 2008-09-15 JP JP2010525902A patent/JP5722037B2/ja not_active Expired - Fee Related
- 2008-09-15 AU AU2008305294A patent/AU2008305294B2/en not_active Ceased
- 2008-09-15 EP EP16160414.5A patent/EP3078662A1/en not_active Withdrawn
- 2008-09-15 DK DK08834504.6T patent/DK2209778T3/da active
- 2008-09-15 KR KR1020107008594A patent/KR101566042B1/ko not_active Expired - Fee Related
- 2008-09-15 US US12/678,995 patent/US8212045B2/en not_active Expired - Fee Related
- 2008-09-15 SI SI200830746T patent/SI2209778T1/sl unknown
- 2008-09-15 CA CA2699718A patent/CA2699718C/en not_active Expired - Fee Related
- 2008-09-15 EP EP13186328.4A patent/EP2727910B1/en not_active Not-in-force
- 2008-09-15 PT PT88345046T patent/PT2209778E/pt unknown
- 2008-09-15 MY MYPI2010001186A patent/MY180558A/en unknown
- 2008-09-15 EP EP12181665A patent/EP2573087A1/en not_active Withdrawn
- 2008-09-15 WO PCT/US2008/076401 patent/WO2009042435A1/en not_active Ceased
- 2008-09-15 ES ES08834504T patent/ES2393824T3/es active Active
- 2008-09-15 EP EP08834504A patent/EP2209778B1/en not_active Not-in-force
- 2008-09-19 TW TW097136197A patent/TWI423799B/zh not_active IP Right Cessation
- 2008-09-19 AR ARP080104095A patent/AR068628A1/es not_active Application Discontinuation
-
2010
- 2010-03-02 IL IL204264A patent/IL204264A/en not_active IP Right Cessation
- 2010-03-04 TN TNP2010000100A patent/TN2010000100A1/fr unknown
- 2010-03-29 ZA ZA2010/02206A patent/ZA201002206B/en unknown
- 2010-04-14 MA MA32775A patent/MA31779B1/fr unknown
- 2010-04-21 CO CO10046631A patent/CO6270223A2/es not_active Application Discontinuation
- 2010-04-21 CR CR11383A patent/CR11383A/es unknown
-
2011
- 2011-03-29 ZA ZA2011/02350A patent/ZA201102350B/en unknown
-
2012
- 2012-06-11 US US13/493,616 patent/US8853409B2/en not_active Expired - Fee Related
-
2014
- 2014-09-23 US US14/494,430 patent/US9079890B2/en not_active Expired - Fee Related
-
2015
- 2015-03-12 CR CR20150131A patent/CR20150131A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10000508B2 (en) | Crystalline dimethyl 3-(benzyloxy)-1-(2,2-dimethoxyethyl)-4-oxo-1,4-dihydropyridine-2,5-dicarboxylate | |
| US8558000B2 (en) | 4-pyridinone compounds and their use for cancer | |
| JP5335932B2 (ja) | 制癌剤である二置換ピリジン誘導体 | |
| CA2746307C (en) | Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors | |
| ZA200504973B (en) | Fuse 1,3-dihydro-imidazole ring compounds | |
| JP5587246B2 (ja) | レニン阻害剤としての3,4−置換ピペリジン誘導体 | |
| TW200804345A (en) | Substituted benzimidazoles and methods of preparation | |
| IL116998A (en) | Indoline compounds, processes for their preparation and pharmaceutical compositions comprising them | |
| JP2006517235A (ja) | N−アリールカルバミン酸エステルとハロ−ヘテロアリールとを反応させることによるn−ヘテロアリール−n−アリール−アミンの調製のためのプロセスおよび類似のプロセス | |
| CA2839699A1 (en) | Trpm8 antagonists and their use in treatments | |
| CA3002632C (en) | Pyrimidine derivative | |
| JP2025520081A (ja) | Trpm3媒介性障害を治療するためのインドリジン誘導体 | |
| JP2013047223A (ja) | 医薬 | |
| CA2615670C (en) | Isotopically substituted proton pump inhibitors | |
| US7601737B2 (en) | Isotopically substituted proton pump inhibitors | |
| MXPA06011993A (es) | Compuesto imidazopiridina. | |
| Cocco et al. | Synthesis and azannulation of pyridinylaminohexadienones | |
| HK1125098B (zh) | 同位素取代的质子泵抑制剂 |